BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
the firm's price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly's stock due to the company's successful obesity product launches and the steady expansion of its pipeline into new therapeutic areas. 2027 projected earnings are expected to better capture the company's long-term growth potential. In other news, on December 12, Eli Lilly and Company announced updated results from the Phase 3 EMBER-3 study for Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist. The data highlighted the efficacy of Inluriyo both as a standalone treatment and in combination with Verzenio (abemaciclib) for patients with ER+, HER2- advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy. In patients with ESR1-mutated disease, imlunestrant monotherapy showed a clinically meaningful 38% reduction in the risk of progression or death. The combination of imlunestrant plus abemaciclib yielded eve
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers [Yahoo! Finance]Yahoo! Finance
- Ovarian cancer survivor on finding hope through cancer clinical trials [CBS News]CBS News
- Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant) [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,000.00 to $1,200.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website